Deniz Can Guven
@DenizCanGuven1
Followers
2K
Following
8K
Media
61
Statuses
2K
Medical Oncologist @myESMO Young Oncologist Committee Member Editorial Board Member in @BMC Cancer, @PLOSONE, @thePeerJ, and @OfOncological
Joined February 2020
Although I am late β²οΈβ²οΈ.I need to say #ESMO24 was really inspiring π€π€. β
The opportunity to follow the cutting-edge research with our friends was amazing π―π―. β
Helping the young oncologists via #ESMOYOC Track activities with my #ESMOYOC family, as well as sharing the stage
1
6
57
#ESMO2023 excitement is continuing β‘οΈβ‘οΈ. We got the best poster award for palliative care .@dromerdizdar @Hacettepe1967. Thank you @myESMO ππ. Lets get another tomorrow again for #ESMOYOC activitiesππ.08:30 YO Fellowship π©βπ«π¨βπ«.11:00 YO Brunch π₯ͺπ₯ͺ.14:45 YO Masterclass ππ
24
18
188
I am humbled and excited to join the @myESMO Young Oncologist Committee #ESMOYOCππ. I would like to thank my family, my mentors from @Hacettepe1967, and the @onkolojidernegi for their supportππ. Looking forward to developing many projects with brilliant colleagues π―π―
6
10
148
I am honored to share with you that I was kindly recognized by @myESMO in the ESMO exam talent pool for 2022 ππ. I would like to thank my mentors from @Hacettepe1967 and @onkolojidernegi, @ESOncology, for their generous support in enabling me to enter the exam ππ
14
3
142
Our systematic review on MSS CRC is out @OncJournal . We reviewed >50 studies on the topic π¦π¦. Main findings.-The ICI monotherapy and ICI-ICI combinations have limited benefitsββ.-A substantial benefit in patients with lung mets in several studies
8
38
136
Out in @Cancers_MDPI . We systemically reviewed the neoadjuvant IO trials in NSCLC ππ. -The use of IO+CT improves DFS (HR: 0.59, 95% CI: 0.52-0.66, p<0.0001) ππ.-The OS improvement was alsoββ(HR: 0.67, 95% CI: 0.55-0.82, p < 0.0001).-pCR in 1/5 patients .-No increase in
4
38
133
Out in @JGeriOnc πππ. We reviewed the available evidence regarding ICI use in patients with frailty ππ. Take home points;.-The available studies mostly used ECOG as a frailty surrogate π§π§.-No increase in irAEs with frailty ββ.-Shortened OS in
4
32
125
New paperβοΈβοΈβοΈ. The survivorship outcomes in patients treated with IO in real-life cohortsπ§π§. -Better QoL with monotherapy and responders β.-Late and long-term irAEs in over 20% of the patients βοΈ.-Significant rates of depression and neurocognitive impairments β οΈ
9
20
123
Proudly sharing my ESMO badge for 2023, inspired from @yekeduz_emre ππ. Will be a great meeting to follow science π§¬π§¬. Excited to be involved in the great #ESMOYOC track organized by @DrJonLim π―π―. We are starting today 16:00 with ESMO YO Mentorship Session βοΈβοΈ
2
8
108
I am honored to share that I graduated from the ESCOπ₯³π₯³.Many thanks for @ESOncology for the continued support to my education ππ.In-line with @ESOncology and ESCO mission, now it is my turn to spread the knowledge that I gained to my younger colleagues π€π€
7
3
90
I am thrilled to share that I was accepted as Editorial Fellow at the Journal of Immunotherapy and Precision Oncology. I am excited to develop as a researcher and writer with the help of a great editorial board and my great co-fellows.βοΈβοΈπ₯Όπ₯Ό.@InnoJournals @JIPOEditors.
2
3
87
On our way to #ESMO23.Young Oncologists From πΉπ·πΉπ·. Excited for high-quality data and great.#ESMOYOC activities ππ. @myESMO @matteolambe @Hasancagri_y @fatihkushh @DrJonLim @EMariamidze @pawel_sobczuk @DrLizConnolly @EMariamidze @DrYukselUrun @yekeduz_emre @dromerdizdar
2
7
86
Thank you very much for highlighting our work @oncodaily ππ.
We got the best poster award for palliative care - @DenizCanGuven1.@dromerdizdar @Hacettepe1967 @myESMO. #Cancer #ESMO #OncoDaily #Oncology #ESMO
2
1
72
Out in @TheLancetOncol in OA. The OS benefits of cancer drugs approved by surrogate endpoints. βοΈ38 indications with OS data after approval.βSignificant OS benefit in only 32% of the indications.βLate availability of (>3 years) non-significant OS results. The value of surrogate
2
25
71
Join us tomorrow for another great #ESMOYOC YO4YO Virtual Session with @DrAngelaLamarca ππ. We will discuss the application to a research fellowship to boost your career ππ. @myESMO @OncoAlert @oncodaily @matteolambe @mkmoutafi @DrHongchengZhu @DrLizConnolly @pawel_sobczuk.
The 2024 YO4YO Virtual Session Series starts soon. Do not miss the chance to follow the Mentorship session w/ @DrAngelaLamarca & @DenizCanGuven1 on how to pave your path to success in #oncology. π
28 Febβ18.00-19.00 CET . π
1
11
54
Out in @jitcancer . A multi-center study on the timing of IO infusion and efficacy βοΈβοΈ. βοΈ201 patients with mRCC.βοΈBetter OS and PFS with IO infusions before noon ππ.βοΈSupport studies in melanoma and NSCLC ββ.πCould be preferable in daily practice until further evidence
1
22
48
Out in Cancer Treatment Reviews ππ. NOM after IO in early-stage MSI-H GI cancers . βHigh pCR rates (>60%).βοΈPrompt consideration in rectal cancer .β οΈInvestigational in gastric and colon cancers. An excellent review π―. @OncologyAdvance @OncoAlert #OncoAlertAF
2
22
48
We are continuing #ESMOYOC activities in #WCGIC2023 today and tomorrow π€π€. Join us .Today 17:10.Pallative/Supportive Care in GI Cancers π©Ήπ©Ή.Jayne Wood and Florian Scotte. Tomorrow 16:45.Complex Clinical Trials in GI Cancers π§©π§©.@JenSeligmann and Dirk Arnold. @WCGIC @myESMO
1
7
44
Our systematic review evaluating the efficacy of immunotherapy in rare cancers is now online π»π»π»π»@CHematology .@aksoysercan @ErulEnes .@OncoAlert @ESOncology @myESMO @Hacettepe1967 .
1
8
40
A fantastic team that I am proud to be a part of πͺπͺ. Hope to achieve great things together for YOs across the globe ππ. Please stay tuned for great #ESMOYOC activities in @myESMO congresses and online π»π». @matteolambe @rillepihlak @DrHongchengZhu @EMariamidze @OncoAlert.
At the @myESMO presidential dinner with the best team ever β€οΈ #ESMOYOC #ESMO23. @DrJonLim @EMariamidze @kfoury_maria @rillepihlak @PabloMando @DenizCanGuven1 @pawel_sobczuk @DrLizConnolly @Rodrosb @kevinpunie @ekocakavuk @DrHongchengZhu @mkmoutafi @OncoAlert
0
7
41
Really interesting article by @niklas_kluemper in EJC π€π€. Post-hoc analyses from the IMvigor211 and IMmotion151 ππ. A simple and cheap predictor of IO efficacy >Blood sodium levels π§π§. Could be very practical and beneficial for the patients π€π€. A great discussion on the
2
14
42
π’Less than three weeks away . Come and join us at #ESMOGI24 π. βοΈNew trials in GI cancers.βοΈEducational sessions.βοΈGreat #ESMOYOC activities.βBonus: Beautiful Munich π©πͺπ©πͺ. @myESMO @ChiaraCrem1 @JeanneTie @HannekevanLaar1 @CathyEngMD @DucreuxMichel @MacarullaTeresa @ESOncology
1
16
40
Just finished reading the @JAMAOnc editorial Anti-TIGIT therapy π€π€. @HajjarJoud, @MDerbalaMD & @ANaingMD offer a compelling perspective on the future of cancer treatment. Truly thought-provoking! π―π―.@weoncologists @MDAndersonNewsΒ @bcmhouston
0
12
36
Excited for the #WCGIC2023. Join us for the recent research in GI cancers and the fantastic #ESMOYOC activities π₯π₯. A Vesalius Talk for Clinician Scientistsπ°π°.A Lounge Session for Palliative Care βοΈβοΈ.A YO Session for Rare GI Cancers and Clinical Trials π€π€. @myESMO @WCGIC
1
9
38
Want to know more about the ADCs in lung and .and breast cancers π€π€. A great review by the giants of the field to start π―π―. βοΈSummary of the available data.βοΈA roadmap for further studies ππ.βοΈEmphasizing the need for collaborations and biomarker-driven approaches ππ.
1
16
38
Another great #ESMOYOC session @myESMO .Last stop at @TraintoESMO ππβ‘οΈA preview of Paris with an emphasis on cliches by @kfoury_maria .Great tips on barriers in Precision Medicine π§¬π§¬.@kevinpunie @aftimosp @quimmateo.A preview of upcoming #ESMOYOC activities in ESMO 2022 π―π―
1
8
35
The first of many by the rising star of @Hacettepe1967 ππ. The sky is the limit for @tkoraysahin π―π―. Glad to have the privilege of growing together π€π€. @OncoAlert.
π’ I am thrilled to share our latest study just published in @Cancers_MDPI . β
Royal Marsden Hospital (RMH) score predicts cancer survival beyond clinical trials. π₯Promising tool for real-world patient care. A huge thank you to @DenizCanGuven1 π. @OncoAlert @oncodaily
1
9
38
#ESMO23 is a week away βοΈβοΈ. All #YoungOncologists are welcome to #ESMOYOC track sessions π€π€. Please hear from our superstar @DrJonLim βοΈβοΈ. @matteolambe @EMariamidze @pawel_sobczuk @mkmoutafi @kfoury_maria @Rodrosb @DrLizConnolly @kevinpunie @myESMO @yekeduz_emre @OncoAlert.
Calling all #YoungOncologists π #ESMO23 YOC representative @DrJonLim on the Track's highlights π.Specially-designed sessions for young oncologists every day of the Congress. See you in Madrid or online π· Registration: @matteolambe @DenizCanGuven1.
1
9
35
A new study evaluating the benefit of immunotherapy use beyond progression by our group was published π₯π₯. @SpringerNature .@yekeduz_emre @ErulEnes @aksoysercan @CkapSaadettin @DrYukselUrun @OncoAlert @Hacettepe1967 @AUTFakultesi .
3
6
34
Our new article focusing on the collateral damage of COVID-19 on cancer care is published in @BMJ_SPCare. @by_aktas @GrkanGner5 @CkapSaadettin @aksoysercan @AksunSeren @Hacettepe1967 @OncoAlert . COVID-19 pandemic: changes in cancer admissions
3
6
33
Our meta-analysis demonstrating significantly lower seroconversion rates to COVID-19 vaccination in patients with cancer is online @FrontOncology @CkapSaadettin @OncoAlert @Hacettepe1967 @ESOncology .
1
9
33
Out in @eClinicalMed . An SR-MA of psychological outcomes in rare cancers π¦π¦. βοΈOver 50.000 patients.βοΈIncreased depression (RRΒ =Β 2.61) and anxiety (RRΒ =Β 2.66).β οΈβ οΈHigher rates of suicide and PTSD.Call for immediate action βΌοΈβΌοΈ. Kudos to all authors @val_yang .#OncoAlert
2
15
32
Live from #ASCO24 #CRC Track β€οΈβπ₯β€οΈβπ₯.Neoadjuvant IBI310 (anti-CTLA-4) plus sintilimab in dMMR CRC by Rui-Hua Xu . Phase 1β£ studyβ‘οΈ101 patients.βοΈpCR ratesβ‘οΈ80% with combination and 47.7% with sintilimab monotherapy.βSerious TRAEs in around 7% of the patients. ππSupports dual IO
1
10
35
Thank you for highlighting our work ππ. Main findings.-AKI in almost 1 of 5 patients treated with IO ππ.-β¬οΈβ¬οΈAKI risk in patients with CKD, hypoalbuminemia, or RAAS inhibitor use.-A need for better onco-nephrology collaboration π€π€. A privilege to be mentored by @Marici18.
The incidence and risk factors for acute kidney injury in pa. : Anti-Cancer Drugs
0
3
32
I will follow #ESMOBreast23 on-line with the generous support of @myESMO and ICF π―π―. I would like thank @myESMO for their continuous support to improve cancer care globally ππ. @matteolambe @kevinpunie @EMariamidze @OncoAlert @TotalHealthConf #ESMOYOC
1
3
33
Another excellent #ESMOYOC session π―π―.Virtual meetings are here to stay π»π».A privilege to learn from the experience of @JDekervel about the virtual presentationsβοΈβοΈ.A great sneak peek of Kenya by @bin_abeid .Looking forward to the next session β‘οΈβ‘οΈ.@myESMO @TraintoESMO
0
2
32
Humbled and honored to complete the editorial fellowship at @JIPOEditors ππ. A great learning experience under the mentorship of @ANaingMD π€π€. Congrats to my fantastic collagues @mirella_nardo @jibranahmed1 @aysunsenturk @s02shambhavi π―π―.
Huge congratulations to the fantastic fellows @s02shambhavi @aysunsenturk @mirella_nardo @DenizCanGuven1 @jibranahmed1! Your completion of @JIPOEditors fellowships is a testament to your incredible dedication . Best wishes for continued success and keep shining brightly!.
0
3
33
The 1st-in-human phase 1 study on arginase inhibitor INCB001158 is out on @BMJOncology ππ. Led by my great mentor @ANaingMD . Tested a strong preclinical hypothesis π€π€. βοΈA total of 107 patients.βοΈMonotherapy or with pembro-.βTolerable with fatigue and GI adverse events
2
8
30
Live from #ASCO24 #GE and #HPB Track π₯π₯. ARMANI Phase III trial by @FilippoPietran4. βοΈRam+Pacli- switch maintenance vs oxaliplatin continuation in HER2- Gastric or GEJ Cancer. βοΈβοΈA +ve studyβ‘οΈOver 3 months PFS gain.βοΈβοΈIncreased OS β¬οΈβ¬οΈ. π§Less than 60% received any
1
11
31
Join us next Monday for a great YO4YO Clinical Case Discussion with the rising star of @AnkaraUni and the young king of #OncTwitter for πΉπ·πΉπ· @Erman_Akkus . Learning from the great mentors @DrYukselUrun @yekeduz_emre and already taking the stageππ. Expect a very strong πΉπ·πΉπ· YOs.
π’ποΈAdd to calendar! π.YO4YO Virtual Clinical Case Discussion session @myESMO #YOC . β
"Approaching a genomic profiling report for choosing the next line of therapy" π§¬. We will present and discuss the cases on Monday 27, 18.00 CEST .Big thanks to @myESMO #YOC for organizing
0
10
31
Live from #ASCO24 #GE and #HPB Track π₯π₯.Early results from PASS-01 study by Jennifer J. Knox. Signature-based treatment selection in mPDACποΈποΈ. βοΈVery detailed biomarker studies π§¬π§¬.βοΈInferior outcomes with FFX in basal type.βοΈCorrelate-guided therapy MTBs in 50% of the
1
11
31
A very important study on the association of irAEs and T-cell receptor beta gene polymorphisms β οΈβ οΈ.@ANaingMD @weoncologists @OncoAlert @oncodaily @aksoysercan @DrYukselUrun @JIPOEditors.
New #JITC article: T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy @DrSapnaPatel @ANaingMD
0
7
32
Our new study on the evaluation of early unplanned readmissions and predisposing factors in hospitalized cancer patients is published @MASCC_JSCC π₯π₯π₯. @dizdar_omd @brahimYahyaAKI1 @engincesmeci @bsayinalp @Hasancagri_y @OncoAlert @CancerCareMASCC.
1
5
29
Our new study focusing on the stage migrations and early cancer mortality is published in @BMJ_SPCare . @Hasancagri_y @ecesmeci1 @enes_ucgul @yagmurtahilli @AksunSeren @oktayhalitakte1 @dizdar_omd @aksoysercan @CkapSaadettin.
1
9
28
We are live at the 9th ESO-ESMO Arab and Southern European Countries Masterclass in Clinical Oncology.βοΈβοΈβοΈβοΈ.A great learning opportunity π€π€π€.#ESOexperience @ESOncology @myESMO
1
3
28
I will follow #ELCC23 online with the generous support of ICF and @myESMO ππ. A fantastic program with.-New trials (CONTACT-01, RESILIENT)β³.-Updates (EMPOWER Lung-3, Checkmate 816, CodeBreaK 200)π. Only issue->Inability to attend #ESMOYOC sessions by @DrJonLim @EMariamidze π―
3
1
28
Plenty to choose from but here are my personal highlights from a fantastic #ESMOBreast24 π―π―. Glad to follow from X by great #ESMOAmbassadors and #ESMOYOC friends @matteolambe @PabloMando and #OncoAlertAF @ElisaAgostinett ππ. @OncoAlert @BreastAdvocate @BreastCaupdates.
1
10
29
Great two days at @myESMO Preceptorship on Prostate Cancer in #Lugano with an exceptional faculty ππ. My learning points π€π€.-Need of RCTs for unanswered questions ββ.-Emphasizing MDT π₯.-Next-gen imaging β’οΈand sequencing π§¬.@Silke_Gillessen @Ecastromarcos @ZilliThomas
0
0
29
Join us for this exciting educational event by @OncoAlert. -A summary of recent updates in oncology ππ.-Opportunity to learn the insights from a fantastic faculty ππ.-A novel concept on the last day of the Colloquium: How to treat cancer in LMICs πππ. Can't wait β³β³.
A warm invitation to the 4th Annual #OncoAlertColloquium π¨.Feb 5-11, 12 noon EST πΊπΈ6pm CETπͺπΊ.an Amazing faculty, Interactive & Completely Free. REGISTER NOW Via Link:. The Colloquium comes to you in partnership with:.@ASTRO_org @ESGO_society @ESSOnews
1
7
29
Join today for another YO4YO session π€π€.Expect a great discussion of AI in pathology and radiology π€π€.#ESMOYOC. @DrHongchengZhu @PrelajArsela @matteolambe @kevinpunie @DrJonLim @EMariamidze @myESMO @mkmoutafi @DrYukselUrun @aksoysercan @oncodaily @OncoAlert @pawel_sobczuk.
Join @DrHongchengZhu @PrelajArsela in the YO4YO HowTO Session on Tuesday 29 August 2023 at 17:00 to learn how to incorporate AI and machine learning in image analysis to stay ahead in the fields of pathology and radiology. π
0
9
27
A great opportunity for young oncologists with a mentorship needπ¨βπ«π©βπ«. Please send your applications until April 16, 2023 β³β³.#ESMOYOC.@myESMO @matteolambe @DrHongchengZhu @kfoury_maria @DrLizConnolly @EMariamidze @pawel_sobczuk @rillepihlak @Rodrosb @ekocakavuk @mkmoutafi.
The ESMO Virtual Mentorship Programme offers ESMO Members under 40 the opportunity to develop their skills, knowledge & experience to progress in their career w/ a 1:1 mentorship. πApply now, deadline 16 AprilΒ 2023.#ESMOYOC @matteolambe
1
5
27
A very packed palliative track in #ASCO24. Led by several studies on telehealth approaches in #PalliativeCare π±βοΈπ». A plenary on #PalliativeCare ππ. @MASCC_JSCC @NicoleKuderer @crisbergerot @helitropen @OncoAlert @dromerdizdar @tkoraysahin @NCISymptomMgmt @EORTC_QLG.
Dear Colleagues, .The @OncoAlert π¨Network Presents OUR Picks of TOP Abstracts to be Presented at #ASCO24 for in #PalliativeCare . This List Curated by @DenizCanGuven1 πΉπ·and @weoncologists πΊπΈ. Discussing:.Abstract 12000.Multi-site randomized trial of stepped palliative care (PC)
3
10
26
Another important study by the rising star of @AnkaraUni @BbaharK ππ. Blood sodium levels π§π§. An accessible and easy to use prognostic biomarker in patients treated with IO ππ.
π«Our new study is out! Hyponatremia negatively impacts prognosis in patients receiving ICI therapy, regardless of etiology. π @DrYukselUrun @yekeduz_emre @Eda_Eylmr_Mcn @coskunyazgann @OncoAlert
1
6
26
Always a pleasure to be in the same room with Erman (actually a foyer this time ππ). After getting accustomed to his great summaries in @X, hopefully, we will see him in person more in congresses, especially in #ESMOYOC activities ππ. Excited to see him grow π―π―.
πWe had a very nice, helpful and enjoyable YO mentorship session!.#ESMOGI24 @myESMO . Thanks @HannekevanLaar1 for her mentorship and YO committee members @DenizCanGuven1 @rillepihlak ππ». Special thanks to @DenizCanGuven1 for his always continuing support π
0
2
27
Just before #ASCO24. The top π abstracts on GI Cancers. Excited to follow practice-changing science in #ASCO24 and share via @OncoAlert network ππ. Not included in the list but highly expected: ESOPEC trial (First time a plenary without new drugs ππ). Watch the #OncoAlertAF.
Dear Colleagues,.The @OncoAlert π¨Network Presents OUR Picks of.TOP πAbstracts to be Presented at #ASCO24 for GI Cancers. This List Curated by: @dr_yakupergun πΉπ· @DenizCanGuven1 πΉπ· @heinrich_kat π©πͺ and @weoncologists πΊπΈ with OncoAlert GI Faculty @BenWestphalen π©πͺ. 1- A phase
0
8
27
A fantastic talk by Frederic Thomas to start the 25th edition of #WCGIC2023. Evolution of Cancer π¦π¦.@myESMO @OncoAlert @TotalHealthConf @WCGIC .#ESMOYOC
0
1
25
Looking forward to another stellar ESMO YOC virtual session π¨βπ»π¨βπ». A stellar faculty @matteolambe @bozovicspa @KathrynRuddyMD π―π―. Case presentations by @osutcuoglu and Dr. Hoang π½οΈπ½οΈ. Expecting significant attendance by the Turkish YO community πΉπ·πΉπ·.
What are the challenges in the management of young women with #BreastCancer? Join @matteolambe @bozovicspa and @KathrynRuddyMD to discuss clinical cases presented by YOs Osman Sutcuoglu and Hoai Hoang #ESMOYOC . π10 July, 18:00 CEST .
1
2
26
Our new paper evaluating the association between the early NLR changes and survival in immunotherapy-treated patients is now online at @JCM_MDPI . .@ErulEnes @enes_ucgul @Hasancagri_y @aksoysercan @CkapSaadettin @Hacettepe1967 @ESOncology @OncoAlert.
1
7
25
One of highligts of the #ESMOGI24 for YOs π. β
Opportunity for networking and mentorship π€.β
Listen the journeys of giants of the field π©ββοΈπ¨ββοΈ.β
Discuss patient management with real-world cases π₯.#ESMOYOC. @myESMO @Erman_Akkus @matteolambe @DrHongchengZhu @ESOncology.
π’ all Young Oncologist attending #ESMOGI24 . We have 3 βΌοΈ amazing sessions specifically for you with these πexcellent speakers π from around the π.Come and join us!
0
10
23
Live from #ASCO24 #GE and #HPB Track π₯π₯. NRG Oncology/RTOG 0848 by @KarynAGoodman.Adjuvant CRT results. βοΈDFS improvement with Cape-RT in all group.βοΈOS and DFS improvement with Cape-RT in N- patients.βοΈNo increase in Gr4-5 AEs. π§Changes in SOC in the adjuvant settingβ‘οΈNo
3
11
26
Join us tomorrow for another great #TrainToESMO session ππ. We will discuss about making climate-friendly changes in your institution and community ππ.#ESMOYOC.@BeckiLee @matteolambe @DrJonLim @EMariamidze @Rodrosb @pawel_sobczuk @DrLizConnolly @Rodrosb @DrYukselUrun @myESMO.
#TrainToESMO: Tomorrow, 28 September, at 18:00 CEST, do not miss the chance to connect with @DenizCanGuven1, @BeckiLee and Angela Hayes and discuss how to deliver meaningful climate-friendly changes in your institution and community. π
1
8
24
A very important update by @CancerCareMASCC and @myESMO and very practical summary by @Erman_Akkus π―π―.
π’ 2023 updated @CancerCareMASCC and @myESMO recommendations for prophylaxis of nausea and vomiting! . β
Olanzapin may be more incorporated in daily pratice. β‘οΈMultiple day cisplatin , ASCT: setron + aprepitant + dexamethasone+ olanzapine . 5 mg once daily at bedtime, until
1
3
25
Our new article on the evaluation of emergency department (ED) π₯visits in patients treated with immune-checkpoint inhibitors (ICIs) π₯π₯π₯. @aksoysercan @CkapSaadettin @dizdar_omd @AksunSeren.
1
4
23
CheckMate 9DW by Robert Galle. Nivo+Ipi- vs Lenva/Sorafenib in 1st line uHCC. β¬οΈA significant OS benefit (23.7 vs 20.6 months).β
Consistent benefit in subgroup analyses.β
Reduced risk of symptom deterioration. A new SOC in uHCC π. #ASCO24 #OncoAlertAF #Checkmate9DW @OncoAlert
0
8
24
Our systematic review and meta-analysis evaluating the pan-immune-inflammation value (PIV) and cancer prognosis is online @Cancers_MDPI .@aksoysercan @CkapSaadettin @ErulEnes .@OncoAlert.
1
5
21
Selecting to an @myESMO Preceptorship βοΈ.Selecting to @ESOncology Masterclass βοΈ. The new rising star of @AnkaraUni ππ.I was able to witness the start of his story π. I am excited to see younger brother grow with the mentorship of @DrYukselUrun π€π€. The sky is the limit π―π―.
Case presentation at the @ESOncology masterclass, invaluable experience for oncology fellows. PS: I also mentioned our hospital with inspiration from Avicenna. Endless thanks to my mentor whose presence in our institute is a great chance for fellows like usπ@DrYukselUrun
1
6
21
Best way to stay updated in the #Oncotwitter π―π―. Great weekly summaries by the Mr. OncoAlert himself π€π€ @weoncologists . Happy to see some friends too πΉπ·πΉπ· @yekeduz_emre @Erman_Akkus . @nataliagandur @acampsmalea @MartaPerachino @heinrich_kat @HHorinouchi @Dr_Ivanoncologo.
The OncoAlertπ¨NEWSLETTER OUT .Covering April 25 to May 1, 2024. REGISTER at OR COVERING.β
DESTINY-Breast06. β
Monarch Eπ¦. β
US Preventive S Task force #BreastCancer Screen
0
6
22
With the generous support of @myESMO and #ICF I will be able to follow the #ESMOImmuno22 onlineπ»π». Looking forward to a great research and education program on immuno-oncology βοΈβοΈ. Many thanks to @myESMO for spreading knowledge to young oncologists from LMICs
0
2
20
Leading the way for younger generations ππ.More than deserving ππ.
π¨I am incredibly excited, happy, and honored to be accepted into the 2023β2024 ASCO Leadership Development Program. I wholeheartedly thank my lifelong mentor and friend @DrChoueiri as well as @DrRanaMcKay and @kcpels for their encouragement and strong support and @ASCO for
1
0
21
In this @JIPOEditors interview, we discussed the CAR-T therapy in solid tumors with Dr. Samer Srourπ€π€. Summary.-An increase in CAR-T trials in solid tumors π.-Problems with combination strategies β οΈ.-Possibly will be in the clinic in the near future β³.
1
1
20
Our paper on the impact of therapy on COVID-19 vaccine efficacy in hematological cancers is out at @OncJournal . - Low seroconversion rates with two-dose vaccination β‘οΈβ‘οΈ.-Concerning seroconversion rates with anti-CD20 (RD: β0.70%) or BTKi (β0.63%) β οΈβ οΈ.
2
5
18
Live from #ASCO24 #GE and #HPB Track π₯π₯. ECOG-ACRIN EA2186 by @efratdotan . βοΈGem+Nab-P vs 5FU+Liposomal Irinotecan in older patients with mPDAC. ππFirst elderly-specific vulnerable population trial completing accrual in mPDAC. βNo significant difference in OS in both arms
0
6
21
Out in @ScienceMagazine . Finding the missing link betweenβοΈ andπ¦. βοΈVit-D availability >β¬οΈ Immune activation and IO efficacy. βοΈRegulation of GI microbiome by Vit-D availability>Role of B. fragilis π¦ π¦ . πPaves the way for more IO and Vit-D studies (PROVIDENCE study). Congrats.
0
7
19
Join us tomorrow for another exciting #TrainToESMO meeting by #ESMOYOC and CCTF ππ. We will discuss making oncology practice more climate-friendly with our great expert @VriesElisabeth . 17:00 pm CEST.18:00 pm πΉπ·πΉπ·. @mkmoutafi @JalvingHilde @matteolambe @oncodaily @myESMO.
#TrainToESMO: Tomorrow, 3 October, at 17:00 CEST connect with @DenizCanGuven1, @mkmoutafi, @JalvingHilde and @VriesElisabeth to discuss how to make oncology practice more climate-friendly, learning from the ESMO-MCBS experience.π
0
7
18
Live from #ASCO24 #GE and #HPB Track π₯π₯.ABC-07 study by Maria A. Hawkins. βοΈGem-Cis +/- SBRT in Locally Advanced CC . ββNo PFS benefitβ‘οΈ-ve for primary endpoint.ββNo statistically significant OS benefit.βοΈLess deaths due to liver failure in SBRT arm ββ. #OncoAlertAF.@ASCO
0
8
20
Live from #ASCO24 #CRC Track β€οΈβπ₯β€οΈβπ₯.COLLISION Study by Martijn Ruben Meijerink.βοΈSurgery vs Thermal Ablation for Small-Size CRC Liver Mets.βοΈOver 600 patients with β€3 cm liver mets/Maximum of ten lesions.βοΈ+ve Study>Non-inferiority was met for OS ββ.βοΈLower rates of AEs with
0
12
20
Two exciting sessions for young oncologists interested in rare cancers ππ.#ESMOSarcomaandrarecancers23.#ESMOYOC.
Coming to #ESMOSarcomaandrarecancers23? Donβt miss out sessions dedicated for young oncologists!.ποΈMon, Feb 20 - Mentorship session.ποΈTue, Feb 21 - Vesalius Talk about career in rare tumors.@myESMO @DrLizConnolly @PabloMando @DenizCanGuven1 @DrJonLim @kfoury_maria @ekocakavuk
0
2
19
Expect another fantastic #ESMOYOC Virtual Session on 14 Dec ποΈποΈ. Correct reporting of Real World Data is critical π¦π¦. An opportunity to gain important insights on the topic from @rdienstmann and our #ESMOYOC πΈπΈ@kfoury_maria . @matteolambe @DrLizConnolly @Rodrosb @DrJonLim.
To learn how to report Oncology Real Word Data?.Join us w/@rdienstmann for the #ESMOYOC Virtual session on 14 Dec 17-18 CET. @matteolambe @DrJonLim @EMariamidze @pawel_sobczuk @PabloMando @ekocakavuk @mkmoutafi @rillepihlak @DenizCanGuven1 @DrLizConnolly @DrHongchengZhu @Rodrosb.
1
4
19
Another great meeting by @myESMO . Expect to see.-Cutting edge research π¨βπ»π¨βπ».-Great education π€π€.-Networking opportunities πΈοΈπΈοΈ. Bonus-Munich π©πͺπ©πͺ. #ESMOYOC.@matteolambe @DucreuxMichel @AndresC27622123 @DrAngelaLamarca @LizzySmyth1 @dizdar_omd @OncoAlert @BenWestphalen.
Mark your agenda for the ESMO Gastrointestinal Cancers Congress 2024 (26-29 June in Munich). For the most impactful new data in #GIoncology, w/ the high-quality educational programme & unrivalled networking opportunities that define ESMO meetings.#ESMOGI24
0
4
19
The OncoAlert newsletter is out ποΈποΈ. Please register at OR . Another comprehensive list of studies lead by IO trials ππ. Stay tuned to stay updated π€π€.@OncoAlert #OncoAlertAF.@ErulEnes @Erman_Akkus @tkoraysahin @onur6191.
The OncoAlertπ¨NEWSLETTER OUT.Covering May 17-23 , 2024. REGISTER at OR Discussing:.β
ICIβs πfor POLE or POLD1 in met CRC.β
Advancements in mgt of Synchronous CRC Liver Mets.β
5yr outcome w/pembroπ mono NSCLCπ«.β
SBRTβ’οΈ in Lung
0
7
17
Live from #ASCO24 #CRC Track β€οΈβπ₯β€οΈβπ₯. Updated results from PANAMA Trial by @ModestDominik .FUFA+/-Panitumumab maintenance in RAS-WT mCRC. βοΈContinued PFS benefit (8.8 vs. 5.8 months).βοΈOS>Not statistically significant (29.9 vs. 24.7 months).βοΈMolecular analysis>Highest benefit in
0
10
18
Always leading by example, a great mentor ππππ @CkapSaadettin.@onkolojidernegi.@Hacettepe1967 @WebTarged.
#WCLC20 #Immunotherapy track Dr. Saadettin Kilickap presents data on EMPOWER-Lung 1 randomized, open label Phase 3 study. The exploratory post hoc analysis assesses the clinical benefits of treatment by randomized sub-population of PD-L1 expression teritles.
0
1
15
Live from #ASCO24 #CRC Track β€οΈβπ₯β€οΈβπ₯.ORCHESTRA Study by Elske C. Gootjes .βοΈSystemic Therapy+/-Debulking Surgery in Multi-Organ Metastatic CRC.βοΈ454 patients with CRC and >80% debulking feasible.βοΈDebulking after two months of systemic therapy.β-ve Study>No survival improvement
0
7
17
Live from #ASCO24 #CRC Track β€οΈβπ₯β€οΈβπ₯. TRANSMET Study by Rene Adam.βοΈCT+/- LT in CRC with Unresectable Liver Mets.βοΈ94 patients/1:1 randomization.βοΈ+ve Study>Improved PFS (HR: 0.34) and 5-year OS (57% vs. 13%) with LT in addition to CT ββ. βοΈCaveats: A heterogenous cohort
1
8
17
Simultaneously on twitter by @dr_yakupergun ππ.
#ESMO23 .ALINA trial: Adjuvant Alectinib vs Chemotherapy . 3y DFS.Stage 1Bβ‘οΈ92.3 vs 71.6% (HR:0.21).Stage 2β‘οΈ95.6 vs 66.3% (HR:0.24).Stage 3β‘οΈ92.7 vs 60.7% (HR:0.25). Practice-changing studyπ₯π₯. Presented by Dr. Ben Solomon. @myESMO
1
1
16
Thank you ESO Ambassadors, it was lovely to meet you all this morning and hopefully next time it will be in person! Keep up the great work sharing your #ESOexperience and informing people about ESO's opportunities.
0
0
15
A great selection of day 1οΈβ£ studies from #ASCO24 coming via @OncoAlert Newsletter ποΈποΈ. Please register at or . #OncoAlertAF.
The @OncoAlert π¨ COVERAGE of DAY ONE #ASCO24 .DELIVERED TO YOU VIA OUR NEWSLETTER. REGISTER at or OncoAlert #Melanoma Faculty.@DrBetofMDPhD @alexshoushtari .OncoAlert #LungCancer Faculty.@ChristianRolfo @GlopesMd @NarjustFlorezMD
0
4
15
A very important finding ππ.Thank you very much for sharing @yekeduz_emre ππ.
π¬ Endocrine gland metastasis is rare in mRCC!.π¬ A NIVOREN trial analysis showed that adrenal metastasis has the worst survival outcomes in pts with mRCC treated with nivolumab after failure of TKI!. @OncoAlert @AlbigesL @DrChoueiri @DrYukselUrun .
0
1
14
Expect a great discussion and update on HR+ breast cancer π§¬π§¬. @matteolambe @dr_yakupergun @ErikaHamilton9 @quirogad @BreastCaupdates @oncodaily @BreastAdvocate @Erman_Akkus.
π@jane_meisel @quirogad are finalizing the upcoming #BCSM #TumorBoardTuesday for 10/03. π΄Join at 8pm ET to discuss CDK4/6i treatment options & breaking updates to ADC use in those with HR+/HER2- met #BreastCancer. ποΈFREE #CME .ππ½οΏ½πΌ
0
4
15
Humbling to be twitter twins with the great @DrYukselUrun. Who is your Twitter twin? π―. @DenizCanGuven1 = @DrYukselUrun. DenizCanGuven1 and DrYukselUrun are Twitter twins!. #twitterTwin #toasteed.
1
0
15
The @OncoAlert π¨Newsletter OUT.Covering June 13-20, 2024. REGISTER at or . Discussing:.β
π« #LungCancer Screening In USπΊπΈ.β
CORE 001πin NMI #BladderCancer .β
Industry Update CAPItello 290.β
Amplifying Patient Voice in Clinical
0
3
15
Key findings ποΈποΈ.-Decreased medical oncology applications ππ.-Increased advanced-metastatic stage disease at the application β οΈβ οΈ.-Decreased diagnosis via screening ππ.-Increased early mortality β οΈβ οΈ. Urgent intervention to protect survival improvements in cancer π¨π¨.
0
1
12
A great initiative with a precious cause π―π―. Humbled and honored to be a part of the great #OncoAlert family ππ. As a medical oncologist from an LMIC, I am more than grateful π«π«. All pharma should support this initiative ππ. @OncoAlert #OncoAlertAF.
0
4
14
We are live β°β°β°.Expecting a great Q&A.
β°οΈ right now: another great discussion from @KoheiShitara at @myESMO Gastric Cancer Guidelines Webinar! . If you miss the live programme catch the recording online at
1
0
13
The @OncoAlert weekly newsletter is out π£π£. Please register at or .
The @OncoAlert π¨Newsletter NOW OUT .Covering July 12-18, 2024 . REGISTER at or Discussing:.β
Industry update on ARANOTE #ProstateCancer.β
IMPASSION132 in #BreastCancer by @RebeccaDSing @JavierCortesMD .β
Panther Trial πΈπͺin
1
3
14
The OncoAlert weekly round-up is here π₯π₯π₯π₯. Make sure to REGISTER at OR βοΈβοΈ. What to expect this week π€π€.Updates from practice-changing trials ππ.Several pivotal policy and prevention trials ππ. Greatly summarized by.
The OncoAlertπ¨ROUND UP.Covering May 2-8, 2024 . REGISTER at OR . β
@TheLancet Commission on #ProstateCancer . β
DESTINY-PanTumor01. β
MONARCH3 π¦in #BreastCancer
0
3
14
πππππ @nahit_sendur.
#WCLC20 Presidential Session: KN598 Pembro-Ipi vs. Pembro in PD-L1-high NSCLC, shows:.- no OS benefit (HR=1.08).- no PFS benefit (HR 1.06).- 20.2% high-grade iraes with combo vs. 7.8% for mono. Pembro is here to stay in PD-L1>50% NSCLC @OncoAlert #LCSM @IASLC
1
0
14